GlassScriptPhysician profile
Mark H Barak
NPI 1467594838
$4,066.42
in general payments reported to CMS, 2019-2025
23 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $221 · 2021: $232 · 2022: $879 · 2023: $967 · 2024: $626 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $621.81 | 2019-2025 | Hydrus Microstent, Clareon |
| Abbvie INC. | $538.72 | 2022-2025 | Xen Glaucoma Treatment System |
| Sight Sciences, INC. | $436.29 | 2021-2025 | Omni Surgical System |
| Amgen INC. | $398.32 | 2024-2025 | Tepezza |
| Dompe US, INC. | $260.08 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $232.57 | 2022-2023 | Tepezza |
| Genentech USA, INC. | $211.46 | 2022-2025 | Vabysmo |
| Lumenis Be INC | $205.77 | 2023 | M22 |
| Ani Pharmaceuticals, INC. | $168.84 | 2024-2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $160.16 | 2020-2022 | |
| Allergan, INC. | $155.37 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $83.90 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $73.43 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $70.19 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $67.48 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $56.71 | 2022-2025 | Tecnis Simplicity |
| Astellas Pharma US INC | $54.69 | 2023 | |
| Bausch & Lomb Americas INC. | $52.89 | 2024-2025 | Scoutpro Osmolarity System, Envista Mx60 Iol, Sofport Ao |
| Glaukos Corporation | $52.65 | 2020-2021 | |
| Rxsight INC | $52.21 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Lombart Brothers, INC. | $46.23 | 2023-2024 | Opd-III |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.49 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $29.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Barak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.